MAPS study
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific launches a 630-patient clinical trial to evaluate the value of target aneurysm recurrence as an endpoint for trials of endovascular devices to treat brain aneurysms. The Matrix and Platinum Science (MAPS) trial randomizes patients with brain aneurysms to be treated with either Boston Scientific's GDC detachable coil or its Matrix2 detachable coil. The primary endpoint of the 50-center trial is target aneurysm recurrence, defined as a composite of target aneurysm reintervention, target aneurysm rupture or rerupture, and death...